Phibro Animal Health Corporation (PAHC) Fair Value 2026

PAHC · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.7 /10

32 fundamental signals · 11 models active

Value Trap Risk

SAFE (16/100)

Quick Summary — As of 2026-08-28, Phibro Animal Health Corporation (PAHC) trades at $37.67, versus a $38.18 median fair value across its 11 active models — 1.4% above the current price. QOC: 8.7/10. Value Trap Risk: 16/100 (SAFE). 11/13 models active.

Key Facts

Ticker
PAHC
Price
$37.67
Quality Score
8.7/10
Value Trap Risk
16/100
Models Active
11/13
Last Updated
Strength: First Chicago suggests +67.3% upside with 67% confidence
Risk: Majority of models suggest overvaluation

Is Phibro Animal Health Corporation (PAHC) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Phibro Animal Health Corporation (PAHC) appears fairly valued as of : the median of 11 independent fair value estimates is $38.18, within 1.4% of the current price of $37.67. Estimates range from $1.12 to $80.50. PAHC scores 8.7/10 on fundamental quality and 16/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. PAHC’s +1.4% gap is narrower than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -8.3%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Phibro Animal Health Corporation Stock in 2026? →

What Fair Value Does Each Model Give PAHC?

11 Intrinsic Value Models vs. Current Price ($37.67)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $17.28 -54.1%
Ensemble · Low Conviction
 $32.29 -14.3%
Scenario · High Conviction
 $63.04 +67.3%
Intrinsic · High Conviction
 $23.47 -37.7%
Unlock the Full Matrix

Access 7 additional models including Markov DDM, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is PAHC's Fair Value Range?

Spread across 11 independent models · $1.12 to $80.50

CirclFi's 11 active models place Phibro Animal Health Corporation (PAHC) between $1.12 and $80.50 per share, a spread of 208% of the median. The median of that range — $38.18 — is the fair value CirclFi publishes for PAHC, against a current price of $37.67.

Low · RCMH-DCFHigh · Regime Cross
$1.12median $38.18$80.50
Where the range comes from
Most bearish modelRCMH-DCF$1.12
Most bullish modelRegime Cross-Sectional$80.50
Model agreement5 bullish · 5 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for PAHC. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on PAHC, not a CirclFi price target. How each model works →

What Is Phibro Animal Health Corporation (PAHC) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Phibro Animal Health Corporation presents a highly debated valuation profile at its current price of $37.67. The median intrinsic value is estimated at $38.18 (+1.4% median upside), masking a wide model spread between the 5 bullish models and 5 bearish models. Model dispersion is worth noting: Regime Cross targets $80.50 (+113.7%), versus RCMH-DCF at $1.12 (-97.0%). This +210.7% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, EPV, EROIC lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About PAHC?

11 of 13 models are currently active for PAHC. Of these, 6 models suggest upside while 5 models suggest overvaluation. Taken together, their median fair value for PAHC is $38.18 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does PAHC Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, PAHC ranks #10 by Quality of Company score. CirclFi's QOC score of 8.7/10 evaluates 32 fundamental signals. A score of 8.7 places PAHC in the top tier.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

Phibro Animal Health Corporation's positioning within the Drug Manufacturers - Specialty & Generic segment means that patent cliff exposure plays an outsized role in fundamental analysis. The sector's unique characteristics — including regulatory pathway clarity — shape both the opportunity set and risk profile.

Is PAHC a Value Trap?

CirclFi's Value Trap algorithm assigns PAHC a score of 16/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Phibro Animal Health Corporation. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Phibro Animal Health Corporation earns a quality score of 8.7/10. This robust rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +210.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PAHC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PAHC's 11 active models, average confidence is 55%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Phibro Animal Health Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

COLLCollegium Pharmaceutical, Inc.QOC 8.8ALKSAlkermes plcQOC 8.6RDYDr. Reddy's Laboratories LimitedQOC 8.8ETSTEarth Science Tech, Inc.QOC 8.5ELTPElite Pharmaceuticals, Inc.QOC 8.8HLNHaleon plcQOC 8.5AKBAAkebia Therapeutics, Inc.QOC 6.6RMTIRockwell Medical, Inc.QOC 5.8CTORCitius Oncology, Inc.QOC 4.4UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: COLL · ALKS · RDY · ETST · ELTP · HLN · AKBA · RMTI · CTOR · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to PAHC?

7 companies across all industries closest to PAHC’s Quality of Company score of 8.7/10.

YOUClear Secure, Inc.QOC 8.7KRTKarat Packaging Inc.QOC 8.7EWEdwards Lifesciences CorporationQOC 8.7IRDMIridium Communications Inc.QOC 8.7KAIKadant Inc.QOC 8.7CFGCitizens Financial Group, Inc.QOC 8.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: YOU · KRT · EW · IRDM · KAI · CFG · NVDA

Where Does PAHC Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

PAHC is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Phibro Animal Health Corporation’s Valuation?

What is Phibro Animal Health Corporation's intrinsic value in 2026?

CirclFi puts Phibro Animal Health Corporation (PAHC)'s intrinsic value at $38.18 — the median of 11 independent model estimates as of 2026-08-28, ranging from $1.12 to $80.50. The Quality of Company score is 8.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PAHC overvalued or undervalued right now?

At $37.67, 6 of 11 active models suggest PAHC may be undervalued, while 5 indicate potential overvaluation. The median of all 11 fair value estimates is $38.18, within 1.4% of the current price of $37.67 — a consensus view that PAHC is fairly valued. The assessment depends on which methodology best fits Phibro Animal Health Corporation's business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 8.7 mean for PAHC?

Phibro Animal Health Corporation's QOC of 8.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on PAHC?

CirclFi analyzes PAHC with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on PAHC?

Of the 11 models currently active on PAHC, Regime Cross-Sectional is the most bullish at $80.50 per share, and RCMH-DCF is the most bearish at $1.12. CirclFi's published fair value for PAHC is the median of that range, $38.18, not either extreme. The gap between the two ends equals 208% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is PAHC a value trap in 2026?

Phibro Animal Health Corporation's Value Trap score is 16/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Phibro Animal Health Corporation (PAHC) has a median fair value of $38.18 — within 1.4% of the current price of $37.67 — as of 2026-08-28.” Source: circlfi.com/stock/PAHC/ · Methodology
Primary sources for this PAHC valuation
  • Financial statements: Phibro Animal Health Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001069899) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PAHC as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on PAHC.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

7 models hidden for PAHC Unlock All 11 — $39/mo